Total Payments
$1.2M
2024 Payments
$2,753
Companies
19
Transactions
1,233
Payment Breakdown by Category
Other$615,099 (52.9%)
Consulting$324,263 (27.9%)
Travel$193,532 (16.6%)
Food & Beverage$23,652 (2.0%)
Education$3,115 (0.3%)
Research$2,753 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $612,279 | 294 | 52.7% |
| Consulting Fee | $324,263 | 127 | 27.9% |
| Travel and Lodging | $193,532 | 421 | 16.6% |
| Food and Beverage | $23,652 | 385 | 2.0% |
| Education | $3,115 | 3 | 0.3% |
| Honoraria | $2,820 | 1 | 0.2% |
| Unspecified | $2,753 | 2 | 0.2% |
Payments by Type
General
$1.2M
1,231 transactions
Research
$2,753
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $277,070 | 284 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $247,241 | 232 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $183,592 | 233 | $0 (2023) |
| AstraZeneca UK Limited | $118,387 | 99 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $95,387 | 124 | $0 (2019) |
| Mylan Specialty L.P. | $74,292 | 103 | $0 (2021) |
| Boehringer Ingelheim International GmbH | $60,613 | 39 | $0 (2021) |
| AstraZeneca AB | $30,311 | 39 | $0 (2019) |
| CSL Behring | $14,305 | 7 | $0 (2019) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $13,414 | 15 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,753 | 2 | Teva Pharmaceuticals USA, Inc. ($2,453) |
| 2023 | $19,455 | 23 | AstraZeneca Pharmaceuticals LP ($10,224) |
| 2022 | $20,009 | 14 | GlaxoSmithKline, LLC. ($9,100) |
| 2021 | $79,970 | 71 | GlaxoSmithKline, LLC. ($45,012) |
| 2020 | $180,892 | 136 | GlaxoSmithKline, LLC. ($88,638) |
| 2019 | $300,319 | 367 | GlaxoSmithKline, LLC. ($103,454) |
| 2018 | $323,876 | 359 | Sunovion Pharmaceuticals Inc. ($87,513) |
| 2017 | $235,140 | 261 | Boehringer Ingelheim Pharmaceuticals, Inc. ($98,638) |
All Payment Transactions
1,233 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/20/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $300.00 | Research |
| Study: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects with Chronic Kidney Disease with Associated Moderate to Severe Pruritus | ||||||
| 05/30/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $2,452.50 | Research |
| Study: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | ||||||
| 09/05/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $8,100.00 | General |
| 08/01/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $145.41 | General |
| 08/01/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $72.00 | General |
| 08/01/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $8.80 | General |
| 07/22/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $78.79 | General |
| Category: Respiratory | ||||||
| 07/22/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: Respiratory | ||||||
| 07/21/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $259.50 | General |
| Category: Respiratory | ||||||
| 07/21/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $134.99 | General |
| Category: Respiratory | ||||||
| 07/21/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: Respiratory | ||||||
| 07/21/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: Respiratory | ||||||
| 07/21/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $48.15 | General |
| Category: Respiratory | ||||||
| 07/20/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $612.38 | General |
| Category: Respiratory | ||||||
| 07/20/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $259.50 | General |
| Category: Respiratory | ||||||
| 07/20/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $209.61 | General |
| Category: Respiratory | ||||||
| 07/20/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $134.99 | General |
| Category: Respiratory | ||||||
| 06/21/2023 | GlaxoSmithKline, LLC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| 06/21/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $284.27 | General |
| 06/08/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $187.37 | General |
| 06/08/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $53.04 | General |
| 06/08/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $8.00 | General |
| 03/01/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,322.79 | General |
| Category: RESPIRATORY | ||||||
| 03/01/2023 | Mylan Inc. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,175.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 02/01/2023 | GlaxoSmithKline, LLC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | Teva Pharmaceuticals USA, Inc. | $2,453 | 1 |
| A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects with Chronic Kidney Disease with Associated Moderate to Severe Pruritus | Galderma Laboratories, L.P. | $300.00 | 1 |
About Dr. Gary Ferguson, M.D
Dr. Gary Ferguson, M.D is a Internal Medicine healthcare provider based in Livonia, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922016385.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Ferguson, M.D has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $2,753 received in 2024. These payments were reported across 1,233 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($612,279).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Livonia, MI
- Active Since 08/03/2006
- Last Updated 12/11/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1922016385
Products in Payments
- TRELEGY ELLIPTA (Drug) $197,550
- BEVESPI AEROSPHERE (Drug) $119,022
- STIOLTO RESPIMAT (Drug) $71,987
- Yupelri (Drug) $65,570
- LONHALA MAGNAIR (Drug) $64,629
- STIOLTO (Drug) $44,156
- UTIBRON (Drug) $26,909
- FASENRA (Drug) $22,123
- SPIRIVA (Drug) $18,342
- SYMBICORT (Drug) $17,932
- BREZTRI AEROSPHERE (Drug) $17,766
- NUCALA (Biological) $16,304
- SPIRIVA RESPIMAT (Drug) $16,278
- BREZTRI (Drug) $16,175
- ANORO ELLIPTA (Drug) $15,252
- Zemaira (Biological) $14,290
- ANORO (Drug) $12,418
- YUPELRI (Drug) $8,375
- ProAir Digihaler (Drug) $7,205
- TUDORZA PRESSAIR (Drug) $4,782
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Livonia
Dr. Steven Katzman, D.o, D.O
Internal Medicine — Payments: $935,319
Internal Medicine $935,319
Dr. Jason Paris, M.d, M.D
Internal Medicine — Payments: $47,232
Internal Medicine $47,232
Ala Shuker, M.d, M.D
Internal Medicine — Payments: $24,416
Internal Medicine $24,416
Dr. Imad George, M.d, M.D
Internal Medicine — Payments: $19,517
Internal Medicine $19,517
Stephanie Diamond
Internal Medicine — Payments: $14,062
Internal Medicine $14,062
Ronald Barnett, Do, DO
Internal Medicine — Payments: $12,402
Internal Medicine $12,402